[
    "hydrochlo\u03c0de (0 300 g, 3 14 mmol) and NEt<sub>3</sub> (0 73 mL, 5 24 mmol) were added. The reaction was stirred 20 mm and applied directly on a silica gel flash chromatography column eluted with</p>0-30% EtOAc in hexane affording the product</p>Step D l-r6-(4-Bromo-2-chlorophenvn-5-r4-chlorophenyl)-3-methylfuror2,3-\u03aclpyndin-2-yll-3- methylbutan- 1 -one The product from Step C (0 35 g, 0 67 mmol) was dissolved in THF (10 mL). Isobutyl magnesium bromide in THF (2 M, 1 mL, 2 mmol) was added and the reaction was stirred for 30 mm. The reaction was quenched with HCl (IM) and EtOAc was added. The \n\n organic layer was separated, washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. The residue was purified by flash chromatography on silica gel gradient eluted with 0-15% EtOAc in hexane affording the title compound. HPLC/MS: 516.1 (M+l), 518.1 (M+3); R, = 4.24 min.</p>Using the procedure described in Step D Reference Example 10, along with the requisite</p>\n 6-(4-Bromo-2-chlorophenyl)-2-(terr-butylsulfonyl)-5-(4-chlorophenyl)-3-methylfuro[<sup>\"</sup>23- \u03acipyridine</p>Step A: l-r6-(4-Bromo-2-chlorophenyl)-2-[(fe/'/-butylthio)methoxy1-5-(4-chlorophenyl)pyridin- 3-yl]ethanone. To the product from Step A Reference Example 5 (5.1 g, 11.7 mmol) in DMF (35 niL) was added cesium carbonate (4.75 g, 14.5 mmol), KJ (0.9 g, 0.58 mmol) and tert- butyl(chloromethyl)sulfide (1.9 g, 14 mmol). The reaction was heated to 45 <sup>0</sup>C for 90 min and additional KI (0.3 g, 1.7 mmol) was added. The reaction was heated an additional 30 min, cooled to rt and 10 % aq NaHSO<sub>4</sub> and EtOAc were added. The organic layer was separated, washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated. The residue was purified by flash chromatography on silica gel gradient eluted with 0-20% EtOAc in hexane affording the product. Step B: l-[6-(4-Bromo-2-chloro\u03c1henyl)-2-r(ter?-butylsulfonyl)methoxy1-5-(4- chlorophenyl)pyridin-3-yllethanone. The product (2 g, 3.7 mmol) from Step A was dissolved in MeCN (12.6 mL) and CH<sub>2</sub>Cl<sub>2</sub> (5.4 mL). The reaction was cooled to -20<sup>0</sup>C, and 3- chloroperoxybenzoic acid (2.5 g, 11.2 mmol) was added. The reaction was allowed to come to rt and stirred for 1 h. EtOAc and saturated aq NaHCO<sub>3</sub> were added. The organic layer was \n\n separated, washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated affording the product</p>Step C: 6-(4-Bromo-2-chlorophenyl)-2-(fe^-butylsulfonv\u03c0-5-r4-chlorophenylV3- methylfuror23-fclpy\u03c0dine. To the product of Step B (2.1 g, 3.68 mmol) in DMF (22 mL) and water (0.77 mL) was added cesium carbonate (4.7 g, 14 mmol) in 3 portions in intervals of 30 min, while the reaction was heated at 138 <sup>0</sup>C for a total of 90 min. The reaction mixture was cooled and diluted with EtOAc and 10 % aq NaHSO<sub>4</sub> The organic layer was collected, washed with water, brine, dried (Na<sub>2</sub>SO<",
    "rred at 70 \u00b0C for 1.5 h. The reaction was cooled to rt and TPAP (24 mg, 0.068 mmol) was added. The reaction stirred at rt for 40 min \n\n and concentrated. The residue was purified by flash chromatography on silica gel gradient eluted with 0-25% EtOAc in hexane affording the title compound. HPLC/MS: 544.0 (M+l), 546.0</p>(M+3); R, = 4.29 min.</p>Reference Example 38</p>\n l-r3-Acetyl-6-(4-Bromo-2-chlorophenyl)-5-(<sup>'</sup>4-chlorophenyl)furo[2,3-\u03ac1pyridin-2-yl]-2- methylpropan- 1 -one</p>Step A: l-[6-(4-bromo-2-chlorophenyl<sup>'</sup>)-3-(l-bromoethyl<sup>'</sup>)-5-(4-chlorophenv\u03c0furo[2,3-Mpyridin- 2-vH-2-methylpropan- 1 -one. To l-[6-(2-chlorophenyl)-5-(4-chlorophenyl)-3-ethylfuro[2,3- b]pyridin-2-yl]-2-methylpropan-l-one (prepared in similar fashion to Reference Example 5 except using ethyl magnesium chloride in Step A to form the 3-propionyl-2-pyridone and then using l-bromo-3-methylbutan-2-one for Step B to form the furopyridine) (1.00 g, 1.93 mmol), NBS (0.354 g, 1.99 mmol) and AIBN (79 mg, 0.483 mmol) was added CCl<sub>4</sub> (12 mL). The reaction was heated to reflux for about 1 hr and then concentrated. The residue was purified by flash chromatography on silica gel gradient eluted with 0-10% EtOAc in hexane affording the product.</p>Step B: l-[6-(4-Bromo-2-chlorophenyl)-5-(4-chlorophenyl)-3-(l-hvdroxyethyl)furor2,3- fc1pyridin-2-yl<sup>~</sup>|-2-rnethylpropan-l-one. To the product of Step A (500 mg, 0.755 mmol) in 1- methyl-2-pyrrolidinone (NMP) (10 mL) was added KI (160 mg, 0.964 mmol) and saturated aq NaHCO3 (about 0.75 mL). The reaction was heated to 100 <sup>0</sup>C and then cooled to rt. The reaction was diluted with EtOAc and washed with brine. The concentrated residue was purified by flash chromatography on silica gel gradient eluted with 0-25% EtOAc in hexane affording the product.</p>Step C: l-[3-Acetyl-6-(4-bromo-2-chlorophenyl)-5-(4-chlorophenyl)furo[2,3-Z?]pyridin-2-yl]-2- methylpropan- 1 -one. To the product of Step B (219 mg, 0.411 mmol) in acetonitrile (4 mL) and CH<sub>2</sub>Cl<sub>2</sub> (2mL) was added TPAP (11.6 mg, 0.033 mmol) and NMO (72.2 mg, 0.616 mmol). The reaction stirred at rt for 25 min and was concentrated. The residue was purified by flash chromatography on silica gel gradient eluted with 0-20% EtOAc in hexane affording the title compound. HPLC/MS: 530.1 (M+l), 532.2 (M+3); R, = 4.32 min. Reference Example 39</p></p>5-methyl-l-rtetrahvdro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- \n\n pyrazole. (Note the title compound was isolated as a mixture of tetrahydropyran regioisomers.) Step A: 4-iodo-5-methyl-l-(tetrahvdro-2H-pyran-2-yl)-lH-pyrazole. To a mixture of 4-iodo-3- methyl-lH-pyrazole (20.9 g, 100 mmol, prepared by the method described by Rodrigues-Franco, M.I., Dorronsoro, L, \u0397ernandex-\u0397igueras, A.I., Antequera, G. Tetrahedron Lett. 2001, 42, 863- 865.), T\u0397F (50 mL), and 3,4-dihydro-2H-pyran (10.0 mL, 110 mmol) was added TFA (0.39 mL, 5 mmol). The mixture was heated to 60\u00b0C fo",
    ".02 (dd, J = 7.94, 1.60 Hz, 1 H); 7.48 (d, J = 7.97 Hz, 1 H); 7.23-7.20 (m, 2 H); 7.17-7.12 (m, 2 H); 2.66 (s, 3 H); 1.45 (s, 9 H).</p>Example 43</p></p>N-r6-r2-Chloro-4-rL2,4-oxadiazol-3-yl)phenyll-5-(4-chlorophenvn-2-r2.2- dimethylpropanoyl)furo[2.3-\u03ac1pyridin-3-yll-2-hvdroxyacetamide Step A: N-r6-r2-Chloro-4-fl.2,4-oxadiazol-3-yl)phenyll-5-(4-chlorophenyl)-2-(2,2- dimethylpropanoyl)furof2,3-\u03ac1pyridin-3-yll-2-hvdroxyacetamide. Using the product of</p>Reference Example 21 and the 2 step procedure described for Example 42 the product was obtained.</p>Step B: N-r6-r2-Chloro-4-\u03c0,2\u039b-oxadiazol-3-yl)phenyl1-5-f4-chlorophenyl)-2-f2,2- dimethylpropanoyl)furo[2,3-\u03ac1pyridin-3-yll-2-hvdroxyacetamide. To the product of Step A (20 mg, 0.03 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added a solution of cesium carbonate in MeOH (0.3 M, 6 mg, 0.018 mmol). The reaction was stirred for 30 min, brine was added and the organic layer was extracted, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and evaporated. The residue was purified by flash chromatography on silica gel gradient eluted with 0-30% EtOAc in hexane affording the title compound. HPLC/MS: 565.0 (M+l), 567.0 (M+3); R, = 4.23 min. <sup>1</sup>H NMR (500 MHz,</p>CHCh -d): \u03b4 11.41 (s, 1 H); 9.12 (s, 1 H); 8.80 (s, 1 H); 8.13 (s, 1 H); 8.04 (d, J = 7.99 Hz, 1 \n\n H); 7.49 (d, J = 8.15 Hz, 1 H); 7.23 (d, J = 8.36 Hz, 2 H); 7.17 (d, J = 8.49 Hz, 2 H); 4.43 (s, 2 H); 1.49 (s, 9 H).</p>BIOLOGICAL EXAMPLE 1 Cannabinoid Receptor- 1 (CBl) Binding Assay. Binding affinity determination is based on recombinant human CBl receptor expressed in</p>Chinese Hamster Ovary (CHO) cells (Felder et al, MoI. Pharmacol. 48: 443-450, 1995). Total assay volume is 250 \u03bcl (240 \u03bcl CBl receptor membrane solution plus 5 \u03bcl test compound solution plus 5 \u03bcl [3HJCP-55940 solution). Final concentration of [3H]CP-55940 is 0.6 nM. Binding buffer contains 5OmM Tris-HCl, pH 7.4, 2.5 mM EDTA, 5mM MgCl2, 0.5mg/mL fatty acid free bovine serum albumin and protease inhibitors (Cat#P8340, from Sigma). To initiate the binding reaction, 5 \u03bcl of radioligand solution is added, the mixture is incubated with gentle shaking on a shaker for 1.5 h at 3O<sup>0</sup>C. The binding is terminated by using 96-well harvester and filtering through GF/C filter presoaked in 0.05% polyethylenimine. The bound radiolabel is quantitated using scintillation counter. Apparent binding affinities for various compounds are calculated from IC50 values (DeBlasi et al., Trends Pharmacol Sci 10: 227-229, 1989).</p>Compounds of the present invention have IC50s of less than 5 micromolar in the CBl binding assay. In particular, compounds of Examples 1 to 43 were assayed in the CBl Binding assay and found to have IC50 values for the human CBl receptor less than 1 micromolar.</p>The binding assay for CB2 receptor is done similarly with recombinant human CB2 receptor expressed in CHO cells. The compounds of the present invention are selective CBl antagonist/inverse agonist compounds having IC50s greater in the CB2 binding assay than in the CBl assay.</p>CBl Receptor Binding Activity for Selected Compounds Example No. CBl binding IC<sub>50</sub> (nM)</p>1 2</p>2 6</p>3 1</p>7 1</p>11 1</p>37 1</p>38 3</p>40 1</p>41 5</p>43 0.4</p>BIOLOGICAL EXAMPLE 2</p>Cannabinoid Receptor- 1 TCBl) Functional Activity Assay. \n\n The functional activation of CBl receptor is based on recombinant human CBl receptor expressed in CHO cells (Felder et al, MoI. Pharmacol. 48: 443-450, 1995). To determine the agonist activity or inverse agonist activity of any test compound, 50 ul of CBl-CHO cell suspension are mixed with test compound and 70 ul assay buffer containing 0.34 mM 3-isobutyl- 1 -methylxanthine and 5.1 uM of forskolin in 96-well plates. The assay buffer is comprised of Earle's Balanced Salt Solution supplemented with 5 mM MgCl2, 1 mM glutamine, 10 mM</p>HEPES, and 1 mg/mL bovine serum albumin. The mixture is incubated at room temperature for 30 minutes, and terminated by adding 30ul/well of 0.5M HCl. The total intracellular cAMP level is quantitated using the New England Nuclear Flashplate and cAMP radioimmunoassay kit. The compounds of Examples 1, 2, 3, 7, 11, 37, 38, 40, 41, and 43 were all tested in the</p>CBl functional activity assay and found to have EC50s less than 20 nanomolar.</p>BIOLOGICAL EXAMPLE 3 Cannabinoid Receptor- 1 (CBl) Functional Antagonist Assay To determine the antagonist activity of test compound, the reaction mixture also contains 0.5 nM of the agonist CP55940 (or 50 nM of methanandamide), and the reversal of the CP55940 (or methanandamide) effect is quantitated with increasing concentration of the test compound. Intracellular cAMP is determined as described above. An IC50 value for the test compound is calculated from the titration curve. Alternatively, a series of dose response curves for the agonist CP55940 (or methanandamide) is performed with increasing concentration of the test compound in each of the dose response curves, and a Schild analysis is carried to calculate the Kb value which is an estimation of test compound binding affinity.</p>The compounds of Examples 1, 2, 3, 7, 11, 37, 38, 40, 41, and 43 were all tested in the CBl functional activity assay and were functional inverse agonists.</p>BIOLOGICAL EXAMPLE 4 Cannabinoid Receptor-2 (CB2) Functional Activity Assay.</p>The functional assay for the CB2 receptor is done similarly with recombinant human CB2 receptor expressed in CHO cells.</p>BIOLOGICAL EXAMPLE 5 GABAa. <sup>3</sup>H-muscimol binding assay</p>Membranes from recombinant Ltk cells expressing human GABA \u03b1i\u03b23\u03b3<sub>2</sub> receptors were suspended in an ice-cold solution of 100 mM KCl, 10 mM KH<sub>2</sub>PO<sub>4</sub>, adjusted to pH = 7.4 with 1 M KOH. Tritiated muscimol (PerkinElmer, Wellesley, MA) at a concentration of 2 nM, and serial five-fold dilutions of test compounds at 10 \u03bcM, 2.0 \u03bcM, 400 nM, 80 nM, 16 nM, 3.2 nM, 0.64 nM and 0.13 nM were mixed in 96-well plates containing 200 \u03bcL of membrane suspension. \n\n Cold muscimol and compound Pl 8 were used as negative and positive controls respectively. The assay mixture was incubated at 4\u00b0C for 2 hours, then harvested on GF/C filter plates and washed with ice-cold 50 mM Tris-Cl buffer. The filter plates were dried and counted in a Wallac MicroBeta\u00ae Trilux detector (Model 1450-030; PerkinElmer, Wellesley, MA), and the data were downloaded and analyzed using Prism 3.0. The activity of compound Pl 8 at 10 \u03bcM was used as reference for the test compounds, and it was expressed as increasing H-muscimol binding by 100%, whereas cold muscimol at 2 \u03bcM antagonized H-muscimol binding by 100%. The tested compound's activity at 10 \u03bcM was expressed as a percentage of compound P18's activity at 10 \u03bcM. The following table shows the GABA activity of the Example compounds expressed as a percentage of the activity of control compound Pl 8. As a reference, the parent compound (the compound not substituted with a R4 heteroaryl, such as pyrazole or 1 ,2,4-oxadiazole, as i"
]